Pipeline Pfizer culls early PD-L1 asset after series of clinical wins, deals in cancer BioSpacePfizer's decision to cut its early-stage cancer asset was due to "strategic business reasons" and not driven by safety or efficacy concerns.PipelineOncologyRead full story pharminent April 24, 2026 (Last updated: April 24, 2026) BioSpace Pfizer’s decision to cut its early-stage cancer asset was due to “strategic business reasons” and not driven by safety or efficacy concerns. PipelineOncologyRead full story Post navigation Previous: Avalyn seeks public debut to support new lung drug formulationsNext: Daiichi Sankyo shares slip after delaying annual earnings report Related Stories Pipeline Beyond GLP1s: The race for nextgen obesity drugs starts in the preclinical models pharminent September 2, 2026 Pipeline Bausch + Lomb advances dry eye disease drug to Phase 3 despite mid-stage fail pharminent August 25, 2026 Pipeline Chasing Dupixent, a biotech aims to make better antibody drugs for eczema pharminent August 11, 2026